| Sign In to gain access to subscriptions and/or personal tools. |
Clinical Biomarkers of Cardiac Injury: Cardiac Troponins and Natriuretic PeptidesClinical Laboratories, Hennepin County Medical Center, Minneapolis, Minnesota 55415, USA Correspondence: Address correspondence to: Fred S. Apple, Hennepin County Medical Center, Clinical Laboratories P4, 701 Park Ave., Minneapolis, Minnesota 55415, USA; e-mail:fred.apple{at}co.hennepin.mn.us Laboratory and clinical medicine groups are actively collaborating and optimizing their individual expertise to potentially prove standardized biomarker assays that will optimize patient care. It is critical as new biomarkers are discovered, that quality specifications be developed prior to approval by regulatory agencies that give supported endorsement for the worldwide marketplace. The laboratory medicine and clinical communities of scientists continues to challenge the biomarker field, working towards developing standard reference materials, and providing quality analytical specifications that, hopefully, will be endorsed by our clinical, in vitro diagnostic and pharmaceutical industry colleagues. This paper will specifically address cardiac troponins and natriuretic peptides.
Key Words: Cardiac troponin immunoassays natriuretic peptides myocardial infarction diagnostics risk stratification standardization
Toxicologic Pathology, Vol. 34, No. 1,
91-93 (2006) |
|
|||

